Shandong Weigao Group Medical Polymer Company Limited (1066) announced plans for the renewal of certain continuing connected transactions, proposed the reappointment of an independent non-executive director, and reported a planned change in company type. According to the announcement, an Extraordinary General Meeting is scheduled on 17 December 2025.
The company intends to extend its Purchase Framework Agreement to 31 December 2027 and set new annual caps of RMB1,100 million and RMB1,210 million for 2026 and 2027. This framework allows the purchase of medical-based products from Weigao Holding Group. Payment terms for these transactions will be settled in advance or within one to six months after acceptance, with prices benchmarked against those offered to independent parties.
Meanwhile, the Logistic Support Services Framework Agreement will also be extended to 31 December 2027, with new annual caps of RMB3,720 million and RMB4,150 million for 2026 and 2027. Logistic Company Group will receive a service fee of not more than 3% of the price paid by customers, with settlement of the remaining funds made to Shandong Weigao Group Medical Polymer within 30 days of receiving customer payment.
Furthermore, the board has proposed to reappoint an independent non-executive director, subject to shareholder approval at the upcoming meeting. The company also plans to modify its registered company type from “Stock Limited Company (Taiwan, Hong Kong, Macao and Domestic Equity Joint Investment, Listed)” to “Stock Limited Company (Hong Kong, Macao and Taiwan Investment, Listed).”
Shareholders are advised to review the meeting details and resolutions for voting at the Extraordinary General Meeting on 17 December 2025.
Comments